Why LYMPHOSEEK®?

A unique advancement

Targets the CD206 receptor, a molecular marker for lymph nodes

Precise lymph node detection

Informs accurate staging and patient management

Enables evaluation

 

References: 1. Wallace AM, Hoh CK, Ellner DO, et al. LYMPHOSEEK: A molecular imaging agent for melanoma sentinel node mapping. Ann Surg Oncol. 2007;14:913-21.2. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2017. 3. Vera, DR, Tokin CA. Tilmanocept: a synthetic receptor-targeted molecule for sentinel lymph node mapping. International Atomic Energy Agency (IAEA) Publication 2014; Chapter X: In Press. 4. Data on file, Cardinal Health. 5. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23 (30):7703-7720.